Related Experiment Video
Updated: Aug 15, 2026
06:39
Curcuminoid-Mediated Antimicrobial Photodynamic Therapy on a Murine Model of Oral Candidiasis
Published on: October 27, 2023
Chemically modified curcumin in periodontal therapy: a scoping review
Vishala Bhargavi Chilukuri1, Rupali Agnihotri2, Deepa G Kamath3
1Department of Periodontology, Manipal College of Dental Sciences, Manipal Academy of Higher Education, Manipal, India.
Evidence-Based Dentistry
|August 13, 2026
Summary
Chemically modified curcumin (CMC) analogues show promise in treating periodontitis by reducing inflammation and protecting bone. Further human trials are needed to confirm their effectiveness in clinical practice.
Area of Science:
- Periodontal medicine
- Drug discovery and development
- Host-modulating therapies
Background:
- Periodontitis is a chronic inflammatory disease driven by dysregulated host response, inadequately managed by conventional biofilm removal.
- Curcumin, a natural compound, possesses anti-inflammatory and antioxidant properties, but its clinical application is limited by poor stability and bioavailability.
- Chemically modified curcumin (CMC) analogues have been developed to enhance curcumin's therapeutic potential for host-modulating treatments.
Purpose of the Study:
- To systematically review and map the existing evidence on the therapeutic potential of chemically modified curcumin (CMC) analogues in managing periodontal disease.
- To assess the efficacy of CMC analogues in addressing the dysregulated host response characteristic of periodontitis.
Main Methods:
- A comprehensive literature search was conducted across major scientific databases (PubMed, EMBASE, Scopus, Web of Science).
- Keywords used included "chemically modified curcumin" and "periodontitis".
- Fifteen original research studies evaluating CMC analogues in periodontitis models were reviewed following PRISMA-ScR guidelines.
Main Results:
- CMC2.24, CMC 2.5, mono-carbonyl analogues (e.g., 1A), and iron-curcumin nanoparticles were frequently studied.
- These analogues demonstrated consistent anti-inflammatory and bone-protective effects in vitro, ex vivo, and animal models.
- CMC analogues effectively suppressed elevated MMP-9 and pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) while enhancing pro-resolving mediators like Resolvin D1.
- CMCs exhibited superior stability and bioavailability compared to traditional curcumin.
Conclusions:
- Chemically modified curcumin analogues effectively mitigate excessive inflammation, tissue degradation, and immune dysregulation in periodontitis.
- CMC2.24 shows significant promise as a host-modulating agent for periodontal therapy.
- Further human clinical trials are essential to validate these preclinical findings and facilitate the integration of CMCs into standard clinical practice.
